Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Significant effects of antiretroviral therapy on global gene expression in brain tissues of patients with HIV-1-associated neurocognitive disorders.

Borjabad A, Morgello S, Chao W, Kim SY, Brooks AI, Murray J, Potash MJ, Volsky DJ.

PLoS Pathog. 2011 Sep;7(9):e1002213. doi: 10.1371/journal.ppat.1002213. Epub 2011 Sep 1.

2.

Systems analysis of human brain gene expression: mechanisms for HIV-associated neurocognitive impairment and common pathways with Alzheimer's disease.

Levine AJ, Miller JA, Shapshak P, Gelman B, Singer EJ, Hinkin CH, Commins D, Morgello S, Grant I, Horvath S.

BMC Med Genomics. 2013 Feb 13;6:4. doi: 10.1186/1755-8794-6-4.

3.

Transcriptome analysis of primary monocytes from HIV-positive patients with differential responses to antiretroviral therapy.

Wu JQ, Sassé TR, Saksena MM, Saksena NK.

Virol J. 2013 Dec 27;10:361. doi: 10.1186/1743-422X-10-361.

4.

Cytokines, Hepatic Fibrosis, and Antiretroviral Therapy Role in Neurocognitive Disorders HIV Related.

Falasca K, Reale M, Ucciferri C, Di Nicola M, Di Martino G, D'Angelo C, Coladonato S, Vecchiet J.

AIDS Res Hum Retroviruses. 2017 Mar;33(3):246-253. doi: 10.1089/AID.2016.0138. Epub 2016 Oct 12.

PMID:
27615271
5.

Common transcriptional signatures in brain tissue from patients with HIV-associated neurocognitive disorders, Alzheimer's disease, and Multiple Sclerosis.

Borjabad A, Volsky DJ.

J Neuroimmune Pharmacol. 2012 Dec;7(4):914-26. doi: 10.1007/s11481-012-9409-5. Epub 2012 Oct 12. Review.

6.

PET brain imaging in HIV-associated neurocognitive disorders (HAND) in the era of combination antiretroviral therapy.

Vera JH, Ridha B, Gilleece Y, Amlani A, Thorburn P, Dizdarevic S.

Eur J Nucl Med Mol Imaging. 2017 May;44(5):895-902. doi: 10.1007/s00259-016-3602-3. Epub 2017 Jan 5. Review.

PMID:
28058461
7.

Cerebrospinal fluid metabolomics reveals altered waste clearance and accelerated aging in HIV patients with neurocognitive impairment.

Cassol E, Misra V, Dutta A, Morgello S, Gabuzda D.

AIDS. 2014 Jul 17;28(11):1579-91. doi: 10.1097/QAD.0000000000000303.

8.

Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders.

Giunta B, Ehrhart J, Obregon DF, Lam L, Le L, Jin J, Fernandez F, Tan J, Shytle RD.

Mol Brain. 2011 Jun 7;4(1):23. doi: 10.1186/1756-6606-4-23. Review.

9.

Dementia and neurocognitive disorders due to HIV-1 infection.

Ances BM, Ellis RJ.

Semin Neurol. 2007 Feb;27(1):86-92. Review.

PMID:
17226745
10.

Current understanding of HIV-associated neurocognitive disorders pathogenesis.

Gannon P, Khan MZ, Kolson DL.

Curr Opin Neurol. 2011 Jun;24(3):275-83. doi: 10.1097/WCO.0b013e32834695fb. Review.

11.

Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort.

Robertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, Evans S, Skiest DJ; A5170 Study Team.

Neurology. 2010 Apr 20;74(16):1260-6. doi: 10.1212/WNL.0b013e3181d9ed09. Epub 2010 Mar 17.

12.

A peripheral monocyte interferon phenotype in HIV infection correlates with a decrease in magnetic resonance spectroscopy metabolite concentrations.

Pulliam L, Rempel H, Sun B, Abadjian L, Calosing C, Meyerhoff DJ.

AIDS. 2011 Sep 10;25(14):1721-6. doi: 10.1097/QAD.0b013e328349f022.

13.

HIV-associated neurocognitive disorders: antiretroviral regimen, central nervous system penetration effectiveness, and cognitive outcomes.

Cross HM, Combrinck MI, Joska JA.

S Afr Med J. 2013 Sep 18;103(10):758-62. doi: 10.7196/samj.6677.

PMID:
24079630
14.

Antiretroviral therapy down-regulates innate antiviral response genes in patients with AIDS in sub-saharan Africa.

Boulware DR, Meya DB, Bergemann TL, Williams D, Vlasova-St Louis IA, Rhein J, Staddon J, Kambugu A, Janoff EN, Bohjanen PR.

J Acquir Immune Defic Syndr. 2010 Dec;55(4):428-38. doi: 10.1097/QAI.0b013e3181ef4963.

15.
16.

Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adults.

Liang EC, Sceats L, Bayless NL, Strauss-Albee DM, Kubo J, Grant PM, Furman D, Desai M, Katzenstein DA, Davis MM, Zolopa AR, Blish CA.

J Virol. 2014 Aug;88(15):8629-39. doi: 10.1128/JVI.01257-14. Epub 2014 May 21.

17.

White matter micro-structural changes in ART-naive and ART-treated children and adolescents infected with HIV in South Africa.

Hoare J, Fouche JP, Phillips N, Joska JA, Paul R, Donald KA, Thomas KG, Stein DJ.

AIDS. 2015 Sep 10;29(14):1793-801. doi: 10.1097/QAD.0000000000000766.

PMID:
26372385
18.

Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy.

Everall I, Vaida F, Khanlou N, Lazzaretto D, Achim C, Letendre S, Moore D, Ellis R, Cherner M, Gelman B, Morgello S, Singer E, Grant I, Masliah E; National NeuroAIDS Tissue Consortium (NNTC).

J Neurovirol. 2009 Sep;15(5-6):360-70. doi: 10.3109/13550280903131915.

19.

Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis.

Gelman BB, Lisinicchia JG, Chen T, Johnson KM, Jennings K, Freeman DH Jr, Soukup VM.

J Neuroimmune Pharmacol. 2012 Sep;7(3):686-700. doi: 10.1007/s11481-012-9345-4. Epub 2012 Mar 6.

20.

Current status of HIV/AIDS in the ART era.

Yoshimura K.

J Infect Chemother. 2017 Jan;23(1):12-16. doi: 10.1016/j.jiac.2016.10.002. Epub 2016 Nov 5. Review.

PMID:
27825722

Supplemental Content

Support Center